The global leader in science services reported Q2 revenue of $10.97bn, representing core organic revenue growth of 13%. $0.63bn came from Covid-19 testing, with new innovations in genomic research and biotherapeutics also launching successfully.
Join our network of executives who receive the MBS News daily, as well as the insights, analysis and our weekly column in The Weekend Edition.
You’ll be able to unsubscribe at any time.